The McNair Group

Oseberg, LLC is a software company based in Oklahoma City, Oklahoma, with an additional office in New Orleans, Louisiana. Founded in 2009, Oseberg specializes in developing software-as-a-service (SaaS) analytics tools tailored for the oil and gas industry. Its platform enables users to efficiently search, map, and analyze public regulatory and county-level data from Oklahoma and Texas, facilitating insights into leasing, drilling, and acquisition opportunities. Oseberg's product suite includes atla, an energy data and mapping engine; soI, a data search tool; oseFrac, a fracturing data solution; dataStream, which connects business intelligence systems to data sources; and oseberg map services. By providing normalized and high-quality fracturing data, Oseberg aims to enhance the decision-making capabilities of oil and gas explorers, ultimately improving operational efficiency within the sector.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.